Zeeshan Jawa, MD
Medical Oncology · Ankeny, IANPI 1891055612
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (53.4%), other and education — rather than concentrated in one kind of arrangement. 32 manufacturers reported payments, led by Novartis at 28.5% of the total. Reporting peaked in 2023 at $1,265 and has fallen 98.9% since, to $14 in 2025.
Across 120 payments — averaging $29.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$1K
- Seagen Inc.$778
- Daiichi Sankyo Inc.$262
- Johnson & Johnson$186
- AstraZeneca$154
- Amgen$131
- plus $1K from 26 others
Across 1 payment — averaging $21,625 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$22K
What the payments were for
- Food & beverage$1,92153%
- Education$82823%
- Other$84824%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 19 | $1,025 |
| Seagen Inc. | 18 | $778 |
| Daiichi Sankyo Inc. | 15 | $262 |
| Johnson & Johnson | 2 | $186 |
| AstraZeneca(2 entities) | 5 | $154 |
| Amgen | 7 | $131 |
| AVEO Pharmaceuticals, Inc. | 3 | $128 |
| Bristol Myers Squibb | 5 | $95 |
| Sanofi-aventis U.S. LLC | 1 | $85 |
| Dova Pharmaceuticals | 6 | $84 |
| Astellas Pharma US Inc | 4 | $72 |
| E.r. Squibb & Sons, L.L.C. | 4 | $60 |
| Tersera Therapeutics LLC | 2 | $55 |
| Pfizer | 3 | $54 |
| Jazz Pharmaceuticals Inc. | 3 | $54 |
| Pharmaessentia USA Corporation | 2 | $37 |
| Ipsen Biopharmaceuticals, Inc | 2 | $36 |
| G1 Therapeutics, Inc. | 2 | $34 |
| Blueprint Medicines Corporation | 2 | $34 |
| Lilly USA, LLC | 2 | $33 |
| Adaptive Biotechnologies Corporation | 2 | $31 |
| Boehringer Ingelheim | 1 | $20 |
| Sanofi | 1 | $18 |
| AbbVie | 1 | $18 |
| Incyte Corporation | 1 | $18 |
| Mirati Therapeutics, Inc. | 1 | $16 |
| CTI Biopharma Corp. | 1 | $15 |
| Stemline Therapeutics Inc. | 1 | $15 |
| Novocure Inc. | 1 | $14 |
| Immunogen, Inc. | 1 | $14 |
| Gilead | 1 | $12 |
| Exelixis Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Erleada$114
How this compares
$3,597 in reported general payments places this provider in the 70th percentile of 47 medical oncology providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 42 | $1,014,845 |
| NubeqaDarolutamide | 35 | $473,982 |
| VerzenioAbemaciclib | 28 | $422,334 |
| XtandiEnzalutamide | 29 | $405,542 |
| KisqaliRibociclib Succinate | 21 | $313,334 |
| CalquenceAcalabrutinib Maleate | 18 | $209,000 |
| Lenalidomide | 13 | $130,260 |
| EliquisApixaban | 127 | $97,045 |
| Abiraterone Acetate | 46 | $68,514 |
| XareltoRivaroxaban | 17 | $17,117 |
| Anastrozole | 285 | $5,417 |
| Letrozole | 234 | $4,970 |
| Gabapentin | 108 | $2,812 |
| Tamoxifen Citrate | 52 | $1,392 |
| Dapsone | 26 | $1,328 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $95 | $1,014,84542 claims |
| Lilly USA, LLCVerzenio, Olanzapine | $33 | $422,83648 claims |
| Astellas Pharma US IncXtandi | $72 | $405,54229 claims |
| NovartisKisqali | $1,025 | $313,33421 claims |
| AstraZenecaCalquence | $154 | $209,00018 claims |
| PfizerEliquis | $54 | $97,045127 claims |
| Johnson & JohnsonXarelto | $186 | $17,11717 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 47 medical oncology providers in Iowa.
Other medical oncology in Ankeny
- Mark WestbergAnkeny$1K
- Joshua LukenbillAnkeny$682
- Robert ShreckAnkeny$125
- Daniel BurokerAnkeny$49
- Thomas BurokerAnkeny$23
- Tara GraffClive$702K
- Jun ZhangIowa City$377K
- Mathew WehbeDes Moines$120K
- Ann StrohCedar Rapids$65K
- Praveen VikasFairfield$30K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.